Prostate Cancer Reports


Volume 3 Supplement 8
August 2015

Home > Prostate Cancer Reports > Volume 3, Year 2015 > Supplement 8, August


CONTENTS



CASE REPORTS
DIAGNOSIS AND EVALUATION
EPIDEMIOLOGY AND RISK FACTORS
OVERALL MANAGEMENT
PROGNOSIS AND OUTCOME
TREATMENT
DEFINITIVE RADIOTHERAPY
HORMONAL THERAPY
METASTATIC PROSTATE CANCER
PSA-ONLY RECURRENCE AFTER TREATMENT WITH CURATIVE INTENT
CASTRATION-RESISTANT  PROSTATE CANCER





CASE REPORTS



Casella R, Bubendorf L, Schaefer DJ, Bachmann A, Gasser TC, Sulser T.
Does the prostate really need androgens to grow? Transurethral resection of the prostate in a male-to-female transsexual 25 years after sex-changing operation.
Urol Int. 2005;75(3):288-90.
Source | Abstract | Similar articles

DIAGNOSIS AND EVALUATION



Clinical diagnosis


Gleason score


Egevad L, Mazzucchelli R, Montironi R.
Implications of the International Society of Urological Pathology modified Gleason grading system.
Arch Pathol Lab Med. 2012 Apr;136(4):426-34. doi: 10.5858/arpa.2011-0495-RA.
Source | Abstract | Full text | Similar articles




Epstein JI, Egevad L, Humphrey PA, Montironi R; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group.
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Am J Surg Pathol. 2014 Aug;38(8):e6-e19. doi: 10.1097/PAS.0000000000000238.
Source | Abstract | Similar articles




Giunchi F, Brunocilla E, Borghesi M, Rizzi S, Ricci MS, Romagnoli D, Martorana G, Schiavina R, Fiorentino M.
Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens.
Clin Genitourin Cancer. 2014 Oct;12(5):325-9. doi: 10.1016/j.clgc.2014.01.009. Epub 2014 Feb 6.
Source | Abstract | Similar articles




Phillips JL, Sinha AA.
Patterns, art, and context: Donald Floyd Gleason and the development of the Gleason grading system.
Urology. 2009 Sep;74(3):497-503. doi: 10.1016/j.urology.2009.01.012. Epub 2009 Apr 18.
Source | Abstract | Full text | Similar articles




Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR.
Gene expression correlates of clinical prostate cancer behavior.
Cancer Cell. 2002 Mar;1(2):203-9.
Source | Abstract | Full text | Similar articles




Walsh PC.
The Gleason Grading System: A Complete Guide for Pathologist and Clinicians
The Journal of Urology,
March 2013Volume 189, Issue 3, Page 1173
Source | Abstract | Full text | Book




Gleason score 6


Swanson GP, Epstein JI, Ha CS, Kryvenko ON.
Pathological characteristics of low risk prostate cancer based on totally embedded prostatectomy specimens.
Prostate. 2015 Mar 1;75(4):424-9. doi: 10.1002/pros.22928. Epub 2014 Nov 21.
Source | Abstract | Full text | Similar articles




Gleason score 7


Huang CC, Kong MX, Zhou M, Rosenkrantz AB, Taneja SS, Melamed J, Deng FM.
Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen.
Am J Surg Pathol. 2014 Aug;38(8):1096-101. doi: 10.1097/PAS.0000000000000235.
Source | Abstract | Similar articles




Lavery HJ, Droller MJ.
Do Gleason patterns 3 and 4 prostate cancer represent separate disease states?
J Urol. 2012 Nov;188(5):1667-75. doi: 10.1016/j.juro.2012.07.055. Epub 2012 Sep 19.
Source | Abstract | Similar articles

EPIDEMIOLOGY AND RISK FACTORS



Red meat


Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM.
Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival.
Cancer Prev Res (Phila). 2011 Dec;4(12):2110-21. doi: 10.1158/1940-6207.CAPR-11-0354. Epub 2011 Sep 19.
Source | Abstract | Full text | Similar articles




Richman EL, Stampfer MJ, Paciorek A, Broering JM, Carroll PR, Chan JM.
Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression.
Am J Clin Nutr. 2010 Mar;91(3):712-21. doi: 10.3945/ajcn.2009.28474. Epub 2009 Dec 30.
Source | Abstract | Full text | Similar articles

OVERALL MANAGEMENT



Overview


Castration-resistant prostate cancer


Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.
Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48. doi: 10.1016/j.critrevonc.2013.11.001. Epub 2013 Dec 2.
Source | Abstract | Full text | Similar articles




Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3.
Source | Abstract | Full text | Similar articles




Gomella LG, Petrylak DP, Shayegan B.
Current management of advanced and castration resistant prostate cancer.
Can J Urol. 2014 Apr;21(2 Supp 1):1-6.
Source | Abstract | Full text | Similar articles

PROGNOSIS AND OUTCOME



Prediction of biochemical recurrence in Gleason 7 prostate cancer


Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM.
Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
BJU Int. 2013 May;111(6):921-7. doi: 10.1111/j.1464-410X.2012.11665.x. Epub 2013 Jan 25.
Source | Abstract | Full text | Similar articles

TREATMENT


DEFINITIVE RADIOTHERAPY



Stereotactic body radiotherapy


Alongi F, Fiorentino A, De Bari B.
SBRT and extreme hypofractionation: A new era in prostate cancer treatments?
Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):411-6. doi: 10.1016/j.rpor.2014.09.005. Epub 2014 Oct 22.
Source | Abstract | Similar articles




Arcangeli S, Agolli L, Donato V.
Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?
Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):425-9. doi: 10.1016/j.rpor.2014.08.001. Epub 2014 Sep 10.
Source | Abstract | Similar articles

HORMONAL THERAPY



Side effects of androgen-deprivation therapy


Allan CA, Collins VR, Frydenberg M, McLachlan RI, Matthiesson KL.
Androgen deprivation therapy complications.
Endocr Relat Cancer. 2014 Aug;21(4):T119-29. doi: 10.1530/ERC-13-0467. Epub 2014 May 28.
Source | Abstract | Full text | Similar articles




Sharifi N, Gulley JL, Dahut WL.
Androgen deprivation therapy for prostate cancer.
JAMA. 2005 Jul 13;294(2):238-44.
Source | Abstract | Full text | Similar articles




Risk of cardiovascular disease


Mongiat-Artus P.
Re: androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Eur Urol. 2008 Jun;53(6):1297. doi: 10.1016/j.eururo.2008.03.022.
Source | Abstract | Full text | Similar articles




Seidenfeld J, Samson DJ, Albertsen PC.
Competing risks for patients with localized prostate cancer.
J Natl Cancer Inst. 2007 Oct 17;99(20):1498-9. Epub 2007 Oct 9.
Source | Abstract | Full text | Similar articles




Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.
Source | Abstract | Full text | Similar articles

METASTATIC PROSTATE CANCER



Chemotherapy and chemohormonal therapy


Agarwal N.
Editorial comment.
J Urol. 2011 Sep;186(3):887; author reply 888. doi: 10.1016/j.juro.2011.04.114. Epub 2011 Jul 24.
Source | Abstract | Similar articles




Beuzeboc P.
Words of wisdom. Re: Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
Eur Urol. 2009 Apr;55(4):992.
Source | Abstract | Full text | Similar articles




Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME.
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
J Urol. 2008 Aug;180(2):565-70; discussion 570. doi: 10.1016/j.juro.2008.04.012. Epub 2008 Jun 12.
Source | Abstract | Full text | Similar articles




Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA.
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
J Urol. 2007 May;177(5):1777-81.
Source | Abstract | Full text | Similar articles




Lucas A, Petrylak DP.
The case for early chemotherapy for the treatment of metastatic disease.
J Urol. 2006 Dec;176(6 Pt 2):S72-5.
Source | Abstract | Similar articles




Raghavan D.
Re: Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
Eur Urol. 2007 Nov;52(5):1530-1.
Source | Abstract | Full text | Similar articles




Womble PR, VanVeldhuizen PJ, Nisbet AA, Reed GA, Thrasher JB, Holzbeierlein JM.
A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
J Urol. 2011 Sep;186(3):882-7. doi: 10.1016/j.juro.2011.04.087. Epub 2011 Jul 24.
Source | Abstract | Similar articles

PSA-ONLY RECURRENCE AFTER TREATMENT WITH CURATIVE INTENT



Assessment of metastases


Acetate positron emission tomography (PET)


Dimitrakopoulou-Strauss A, Strauss LG.
PET imaging of prostate cancer with 11C-acetate.
J Nucl Med. 2003 Apr;44(4):556-8.
Source | Abstract | Full text | Similar articles




Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ.
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
J Nucl Med. 2003 Apr;44(4):549-55.
Source | Abstract | Full text | Similar articles




Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R.
18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
BJU Int. 2007 Jun;99(6):1415-20. Epub 2007 Apr 8.
Source | Abstract | Full text | Similar articles

CASTRATION-RESISTANT  PROSTATE CANCER



Background, overview and outlook


Liu JJ, Zhang J.
Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
Cancer Control. 2013 Jul;20(3):181-7.
Source | Abstract | Full text | Similar articles